 | |
| Clinical data | |
|---|---|
| Trade names | Starlix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699057 |
| License data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 98% |
| Eliminationhalf-life | 1.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.170.086 |
| Chemical and physical data | |
| Formula | C19H27NO3 |
| Molar mass | 317.429 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Nateglinide (INN, trade nameStarlix) is adrug for the treatment oftype 2 diabetes. Nateglinide was developed byAjinomoto, a Japanese company and sold by the Swiss pharmaceutical companyNovartis.
Nateglinide belongs to themeglitinide class of blood glucose-lowering drugs.
Nateglinide lowers blood glucose by stimulating the release ofinsulin from thepancreas. It achieves this by closingATP-dependentpotassium channels in the membrane of theβ cells. This depolarizes theβ cells and causesvoltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, andinsulin secretion occurs.
Nateglinide is contraindicated in patients who:
A study funded byNovo Nordisk, the U.S. distributor forRepaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."
Nateglinide is delivered in 60 mg & 120 mg tablet form.
